Lipoic acid acylated salicylate derivatives and their uses
AssigneeCatabasis Pharmaceuticals, Inc.
InventorsJill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
Life of this patent
Estimating the term…
Abstract
The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.
Claims20
A molecular conjugate comprising a lipoic acid and an ortho salicylate wherein the lipoic acid and the ortho salicylate are conjugated through at least two amides.
A compound of Formula I:
- or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof;
- wherein
- R1, R2, R3, and R4 are each independently selected from the group consisting of H, Cl, F, CN, NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —C(O)H, —C(O)C1-C3 alkyl, —C(O)OC1-C3 alkyl, —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)N(C1-C3 alkyl)2, —C1-C3 alkyl, —O—C1-C3 alkyl, —S(O)C1-C3 alkyl, and —S(O)2C1-C3 alkyl;
- W1 and W2 are each independently S, NR, or W1 and W2 can be taken together can form an imidazolidine or piperazine group;
- each symbol ----- represents an optional bond, which when present between the phenolic oxygen and the methylene containing substituent a, requires that Q is null, or when present between substituent a and the carbon of the methylene containing substituent a, requires that Q not be null;
- each a, b, c, and d is independently —H, -D, —C1-C3 alkyl, —O—C1-C3 alkyl, —C(O)OR, —O—Z, or benzyl, or two of a, b, c, and d can be taken together, along with the single carbon to which they are bound, to form a cycloalkyl or heterocycle;
- each n, o, p, and q is independently 0, 1, or 2;
- each L is independently —O—, —S—, —S(O)—, —S(O)2—, —S—S—,-(C1-C6alkyl)-
- wherein the representation of L is not limited directionally left to right as is depicted, rather either the left side or the right side of L can be bound to the W1 side of the compound of Formula I;
- each g is independently 2, 3 or 4;
- each h is independently 1, 2, 3 or 4;
- m is 0, 1, 2, or 3;
- if m is more than 1, then L can be the same or different;
- each R5 is independently H or C1-C6 alkyl, or both R5 groups, when taken together with the nitrogen to which they are attached, can form a heterocycle;
- each R6 is independently e, H, or straight or branched C1-C10 alkyl which can be optionally substituted with OH, NH2, CO2R, CONH2, phenyl, C6H4OH, imidazole or arginine;
- each e is independently H or any one of the side chains of the naturally occurring amino acids;
- each Z is independently H, or
- with the proviso that there is at least one
- in the compound;
- each t is independently 0 or 1;
- Q is null, C(O)CH3, Z,
- W3 is null, —O—, or —N(R)—;
- each R is independently H, —C(O)—C1-C3 alkyl, or straight or branched C1-C4 alkyl optionally substituted with or halogen;
- and
- T is H, C(O)CH3, or Z.
A pharmaceutical composition comprising a molecular conjugate comprising a lipoic acid and an ortho salicylate wherein the lipoic acid and the ortho salicylate are conjugated through at least two amides and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.